[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510300":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":43,"responsibleParty":61,"collaborators":26,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Calgary","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Moderate Dietary Salt Plus Additional Salt","EXPERIMENTAL","6 grams of salt in slow release capsules combined with 6 grams of salt in the diet.",[13],"Dietary Supplement: Sodium Chloride Capsules",{"label":15,"type":16,"description":17,"interventionNames":18},"Moderate Dietary Salt Alone","PLACEBO_COMPARATOR","6 grams of microcrystalline cellulose in slow release capsules combined with 6 grams of salt in the diet.",[19],"Other: Microcystalline Cellulose Capsules",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Sodium Chloride Capsules","Table salt in slow release capsules.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Microcystalline Cellulose Capsules","Microcrystalline Cellulose Capsules (Placebo)",[15],[32],{"name":33,"affiliation":5,"role":34},"Satish R Raj","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Satish R Raj, MD MSCI","CONTACT","4032106152","autonomic.research@ucalgary.ca",{"name":42,"role":38,"phone":26,"phoneExt":26,"email":40},"Tanya Siddiqui, MBBS",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Calgary","Alberta","T2N 4Z6","Canada","CA",{"type":52,"coordinates":53},"Point",[54,55],-114.08529,51.05011,{"lat":55,"lon":54},[58],{"name":59,"role":38,"phone":60,"phoneExt":26,"email":40},"Satish R Raj, MD, MSCI","403-210-6152",{"type":62,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100510300","calgary-salt-for-pots-100510300",false,"NCT05924646","CAlgary SAlt for POTS","CAlgary SAlt for Postural Orthostatic Tachycardia Syndrome Study","CASA-POTS","Inclusion Criteria:\n\n* Physician Diagnosis of POTS as defined by the CCS Consensus Statement and as follows:\n* Sustained, excessive orthostatic tachycardia ≥ 30 bpm within 10 minutes standing.\n* Absence of orthostatic hypotension (\\>20\u002F10 mmHg decrease) within 3 minutes standing.\n* Chronic orthostatic symptoms that improve with recumbence.\n* Age 18-60 years old.\n* Ability to attend the Calgary Autonomic Research Clinic in Calgary.\n* Resident of Canada\n\nExclusion Criteria:\n\n* Overt cause for postural tachycardia (i.e., acute dehydration, thyroid disease)\n* Participants with somatization or severe anxiety symptoms will be excluded\n* Pregnant (self-reported)\n* Underlying causes of tachycardia including acute hypovolemia, endocrinopathy, anemia, anxiety, medication effects, recreational drug effects, and prolonged bedrest.\n* Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies\n* Fludrocortisone use (due to effects on renal Na+ handling)\n* Patients who have received IV saline in the 2 months preceding the study or who plan to receive it during the course of the study","ALL","18 Years","60 Years",{"count":75,"type":76},50,"ESTIMATED","INTERVENTIONAL",[79],"NA","Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend \\~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. This randomized, placebo-controlled cross-over trial will evaluate a high salt diet, compared to a normal salt diet over a period of 3 months. Participants will complete 3 in lab evaluations including autonomic function testing, tilt table testing, blood volume and urine sodium evaluation, plasma catecholamine measurements and and cytokine measurements.",[82],"Postural Orthostatic Tachycardia Syndrome",[84,85,86],"Sodium","Salt","Treatment","2026-04-30",{"date":89,"type":90},"2026-05-07","ACTUAL",{"date":92,"type":90},"2024-05-07",{"date":94,"type":76},"2028-12-31",{"name":5,"class":6},1]